Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy
ASH 2025
Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission who were treated with CD19-directed CAR T-cell therapy. Researchers found the therapy was safe, resulted in low-grade adverse events, and led to preliminary durable measurable residual disease response (Abstract 443).
The ASCO Post Staff
Dory Abelman, PhD(c), HBHSc, of the University of Toronto, discusses findings that support the feasibility of ultradeep cell-free DNA whole-genome sequencing for comprehensive genomic profiling in patients with multiple myeloma, which may be a less invasive alternative to bone marrow biopsy (Abstract 495).
The ASCO Post Staff
Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this subtype (Abstract 236).
The ASCO Post Staff
Benjamin Diamond, MD, of the University of Miami, describes findings from the single-center phase II REKINDLE trial, which looked at the combination regimen of iberdomide, carfilzomib, daratumumab, and dexamethasone in patients with early relapsed/refractory multiple myeloma (Abstract 251).
The ASCO Post Staff
Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses results of a retrospective analysis from the phase II MagnetisMM-3 trial. A post hoc analysis was conducted of the subgroup of patients enrolled in the study who had a prolonged treatment interruption or who permanently discontinued elranatamab and maintained their responses for 6 months or longer (Abstract 2269).
The ASCO Post Staff
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or BCL-2 inhibitors (Abstract 87).
